Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis
- 12 September 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (5) , 804-808
- https://doi.org/10.1212/01.wnl.0000234064.17156.03
Abstract
Objective: To investigate whether relapses contribute to the development of subsequent sustained increase of impairment and disability in patients with multiple sclerosis (MS). Methods: In a random sampled subset of 256 relapsing-remitting MS (RRMS) patients from the placebo arms of 20 randomized, controlled clinical trials contained in the Sylvia Lawry Centre for MS Research (SLCMSR) open database (mean follow-up time 2.66 years), the authors tested whether time to an increase of the Expanded Disability Status Scale (EDSS) score (confirmed after 6 months) was related to the occurrence of prior relapses. In the primary analysis, EDSS progressions starting within the period used to calculate the on-study relapse rate (sacrifice period) were not counted. The result obtained was then validated in an independent validation part of the SLCMSR database (n = 320). Results: Although in the first subset of 256 RRMS patients, occurrence of relapses in the first 4 months on study appeared to be the best predictor for a shorter time to subsequent sustained increase in the EDSS score (hazard ratio [HR] 2.26 [95% CI: 1.36 to 3.75]), this finding was not confirmed in the validation dataset (HR 1.35, one-sided Wald test, lower limit of the 95% CI: 0.90). Conclusion: Although relapses may result into permanent damage and Expanded Disability Status Scale (EDSS) progression, there is no consistent effect of on-study relapses on the subsequent development of sustained EDSS score increase during a typical clinical study observation period.Keywords
This publication has 17 references indexed in Scilit:
- Interferon beta-1b in secondary progressive MSNeurology, 2004
- Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic processBrain, 2003
- The natural history of multiple sclerosis: a geographically based studyBrain, 1999
- An ideal worth fighting forThe Lancet, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisPublished by Elsevier